[go: up one dir, main page]

ATE340563T1 - DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT - Google Patents

DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT

Info

Publication number
ATE340563T1
ATE340563T1 AT01906794T AT01906794T ATE340563T1 AT E340563 T1 ATE340563 T1 AT E340563T1 AT 01906794 T AT01906794 T AT 01906794T AT 01906794 T AT01906794 T AT 01906794T AT E340563 T1 ATE340563 T1 AT E340563T1
Authority
AT
Austria
Prior art keywords
shell
dosage form
release
active ingredients
zero order
Prior art date
Application number
AT01906794T
Other languages
English (en)
Inventor
Bret Berner
Jenny Louie-Helm
Gloria Gusler
John N Shell
Original Assignee
Depomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23983134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE340563(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Depomed Inc filed Critical Depomed Inc
Application granted granted Critical
Publication of ATE340563T1 publication Critical patent/ATE340563T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01906794T 2000-02-04 2001-01-30 DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT ATE340563T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49894500A 2000-02-04 2000-02-04

Publications (1)

Publication Number Publication Date
ATE340563T1 true ATE340563T1 (de) 2006-10-15

Family

ID=23983134

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01906794T ATE340563T1 (de) 2000-02-04 2001-01-30 DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT

Country Status (12)

Country Link
US (6) US7736667B2 (de)
EP (1) EP1251832B1 (de)
JP (1) JP2003521507A (de)
AT (1) ATE340563T1 (de)
AU (1) AU767812B2 (de)
CA (1) CA2396782A1 (de)
DE (1) DE60123384T2 (de)
ES (1) ES2270982T3 (de)
IL (2) IL150568A0 (de)
MX (1) MXPA02007254A (de)
PT (1) PT1251832E (de)
WO (1) WO2001056544A2 (de)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
AU2001292185A1 (en) 2000-10-12 2002-04-22 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
CA2725833A1 (en) * 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
US20040202718A1 (en) * 2001-09-28 2004-10-14 Tyebji Ziauddin Z. Dosage form for treatment of diabetes mellitus
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP1438027A1 (de) 2001-10-25 2004-07-21 DepoMed, Inc. Behandlungsmethode unter verwendung einer losartan enthaltenden darreichungsform mit verlängerter magenverweilzeit
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2003211146B2 (en) * 2002-02-21 2007-07-19 Valeant International (Barbados) Srl Controlled release dosage forms
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
EP1515701B1 (de) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Verfahren zur herstellung von mehrschichtigen tabletten die thiazolidinedione und biguanide enthalten
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
BRPI0406749A (pt) 2003-01-13 2005-12-20 Dynogen Pharmaceuticals Inc Métodos relacionados ao tratamento de distúrbios fincionais do intestino e composição farmacêutica
KR100772980B1 (ko) * 2004-04-01 2007-11-02 한미약품 주식회사 메트포르민의 경구투여용 서방성 제제
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
CN100459982C (zh) * 2004-08-30 2009-02-11 鲁南制药集团股份有限公司 去氧氟尿苷的分散片剂型
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
US20070021379A1 (en) 2005-07-11 2007-01-25 Pharmena North America Inc. Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities
US20070148227A1 (en) * 2005-12-27 2007-06-28 Hemant Joshi Physically/molecularly distributed and/or chemically bound medicaments in capsule shells
US8728521B2 (en) * 2005-12-27 2014-05-20 Hemant N. Joshi Physically/molecularly distributed and/or chemically bound medicaments in empty, hard capsule shells
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
WO2008073282A2 (en) * 2006-12-07 2008-06-19 Schering Corporation Ph sensitive matrix formulation
WO2008153882A1 (en) * 2007-06-11 2008-12-18 Appleton Papers Inc. Benefit agent containing delivery particle
WO2009017716A2 (en) * 2007-07-27 2009-02-05 Depomed, Inc. Pulsatile gastric retentive dosage forms
US8329750B2 (en) * 2008-02-11 2012-12-11 Depomed, Inc. Methods for treating vasomotor symptoms using GABA analogs in a gastric retentive dosage form
AU2009223061B2 (en) 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009246926B2 (en) 2008-05-15 2014-06-26 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
CN102202656A (zh) 2008-08-15 2011-09-28 蒂宝制药公司 治疗和预防cns障碍的胃滞留药用组合物
AU2010245932B2 (en) 2009-05-05 2015-08-06 Board Of Regents, The University Of Texas System Novel formulations of volatile anesthetics and methods of use for reducing inflammation
US20110052700A1 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of levosulpiride
KR20120059582A (ko) * 2009-08-31 2012-06-08 데포메드 인코퍼레이티드 아세트아미노펜의 속방성 및 서방성을 위한 위 체류 약제학적 조성물
US20110104273A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of phenylephrine
US20110104272A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine
CA2783342A1 (en) * 2009-12-08 2011-06-16 Depomed, Inc. Gastric retentive pharmaceutical compositions for extended release of polypeptides
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
EP2389934A1 (de) * 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Tablettenformulierungen mit Pregabalin mit gesteuerter Freisetzung
CN103347517B (zh) 2010-08-11 2018-10-02 德雷克塞尔大学 治疗帕金森病中运动障碍的d3多巴胺受体激动剂
CA2850468C (en) 2010-09-28 2019-08-13 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
EP2648754A4 (de) 2010-12-07 2016-02-24 Philadelphia Health & Educatio Verfahren zur hemmung von krebs-metastasen
US9532977B2 (en) 2010-12-16 2017-01-03 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
US20140018404A1 (en) 2010-12-16 2014-01-16 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
CN104873455B (zh) * 2010-12-22 2023-09-12 普渡制药公司 包覆的抗篡改控制释放剂型
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
PT2688556E (pt) * 2011-03-25 2015-09-11 Purdue Pharma Lp Formas de dosagem farmacêutica de libertação controlada
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
DE102011051653A1 (de) 2011-07-07 2013-01-10 Lts Lohmann Therapie-Systeme Ag Quellfähige Manteltablette
HK1200716A1 (zh) 2011-11-01 2015-08-14 细胞基因公司 使用胞苷類似物的口服製劑治療癌症的方法
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013091093A1 (en) * 2011-12-21 2013-06-27 Eatlittle, Inc. Pseudobezoar-based intraluminal gastrointestinal cleansing and biopsy
KR101699822B1 (ko) 2011-12-21 2017-01-25 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
AU2013292519B2 (en) 2012-07-19 2017-12-07 Drexel University Sigma receptor ligands for modulating cellular protein homeostasis
ES2689906T3 (es) 2012-08-09 2018-11-16 Dynamis Therapeutics, Inc. Meglumina para reducir los niveles altos de triglicéridos
EP2941233B1 (de) 2013-01-07 2020-10-07 The Trustees of the University of Pennsylvania Zusammensetzungen und verfahren zur behandlung von t-zelllymphom
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN105431144A (zh) 2013-06-05 2016-03-23 思康脑侒股份有限公司 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
EP3017054B1 (de) 2013-07-02 2019-11-13 EcoPlanet Environmental LLC Rezepturen aus flüchtigen organischen verbindungen mit antimikrobieller wirkung
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US9908915B2 (en) 2013-11-26 2018-03-06 Yale University Cell-penetrating compositions and methods using same
EP3079692A4 (de) 2013-12-09 2017-10-18 Thomas Jefferson University Neuartiges verfahren zur behandlung einer neurodegenerativen krankheit bei einem säugetier mit derartigem bedarf
US9982010B2 (en) 2014-04-07 2018-05-29 Women & Infants Hospital Of Rhode Island 7-dehydrocholesterol derivatives and methods using same
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CA2949372C (en) 2014-06-02 2023-08-22 Teva Pharmaceutical Industries Ltd. Expandable gastroretentive dosage form
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
US10799541B2 (en) 2014-07-01 2020-10-13 Probi USA, Inc. Bi-layer dual release probiotic tablets
US10624917B2 (en) 2014-08-20 2020-04-21 Yale University Compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
EP3925609B1 (de) 2014-08-22 2025-07-30 Celgene Corporation Verfahren zur behandlung von multiplem myelom mit immunmodulatorischen verbindungen in kombination mit antikörpern
WO2016033295A1 (en) * 2014-08-27 2016-03-03 The Regents Of The University Of Colorado, A Body Corporate Multilayer polymeric matrix based medical devices
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US9579289B2 (en) 2015-02-20 2017-02-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
WO2016182968A1 (en) 2015-05-08 2016-11-17 Brown University Novel syringolin analogues and methods of making and using same
EP3298140B1 (de) 2015-05-19 2024-04-24 Yale University Zusammensetzungen zur behandlung pathologischer calcifizierungserkrankungen und verfahren mit verwendung davon
US10829440B2 (en) 2015-06-12 2020-11-10 Brown University Antibacterial compounds and methods of making and using same
CN108289849A (zh) 2015-06-26 2018-07-17 韩国联合制药株式会社 莫沙必利与雷贝拉唑的复合制剂
WO2017003822A1 (en) 2015-06-30 2017-01-05 Galleon Pharmaceuticals, Inc. Novel breathing control modulating compounds, and methods of making and using same
WO2017029302A1 (en) * 2015-08-18 2017-02-23 Basf Se Agrochemical microcapsules with a shell of polyvinylalcohol and polyoxazoline
ES2897959T3 (es) 2015-10-15 2022-03-03 Servier Lab Terapia de combinación para tratar neoplasias malignas
IL311873A (en) 2015-10-15 2024-06-01 Agios Pharmaceuticals Inc Combination therapy for treating malignancies
CA3002029A1 (en) 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
EP3368505B1 (de) 2015-10-28 2023-02-22 Yale University Chinolinamide und verfahren zur verwendung davon
EP3373916A1 (de) 2015-11-11 2018-09-19 Celgene Corporation Orale retard-darreichungsformen von schwer löslichen arzneimitteln und verwendungen davon
AU2016355715A1 (en) 2015-11-20 2018-05-31 Yale University Compositions for treating ectopic calcification disorders, and methods using same
IL299563A (en) 2015-12-04 2023-02-01 Agios Pharmaceuticals Inc Methods of treatment of acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras
CA3015753A1 (en) 2016-02-26 2017-08-31 Celgene Corporation Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
EP3448369B1 (de) 2016-04-29 2025-06-25 The Regents of The University of Colorado, A Body Corporate Hemmung oder abbau von hdac11 zur behandlung von fettleibigkeit, hyperlipidämie, typ-ii-diabetes, metabolischem syndrom oder insulinresistenz, und zur förderung der gewichtsabnahme und/oder zur linderung oder verhinderung einer gewichtszunahme
US20210330599A1 (en) 2016-08-01 2021-10-28 University Of Rochester Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
US20180042930A1 (en) 2016-08-03 2018-02-15 Celgene Corporation Methods of treatment of malignancies
US11390859B2 (en) 2016-08-05 2022-07-19 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
WO2018045229A1 (en) 2016-09-01 2018-03-08 Mebias Discovery Llc Substituted ureas and methods of making and using same
CN110114071B (zh) 2016-11-07 2023-07-04 爱彼特生物制药公司 含有取代的吡啶酮的三环化合物以及使用其的方法
CN110035718B (zh) 2016-12-02 2021-04-06 克雷西奥生物科技有限公司 胃内滞留系统
EP3571196B1 (de) 2017-01-19 2023-01-04 Temple University Of The Commonwealth System Of Higher Education Neuartige verbrückte bicycloalkyl-substituierte aminothizole und verfahren zu deren verwendung
MA49014A (fr) 2017-03-21 2020-02-05 Arbutus Biopharma Corp Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
IL270070B2 (en) 2017-04-17 2023-09-01 Univ Yale Compounds, compositions and methods for treating or preventing acute lung injury
EP3618828B1 (de) 2017-05-05 2023-11-01 Memorial Sloan Kettering Cancer Center Verfahren zur behandlung von myeloproliferativem neoplasma
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
CN110996922A (zh) * 2017-06-16 2020-04-10 卡希夫生物科学有限责任公司 用于持续药物递送的胃滞留剂型
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
EP3659307A4 (de) 2017-07-28 2021-09-22 Yale University Antikrebsmittel und verfahren zur herstellung und verwendung davon
KR20200072478A (ko) 2017-09-08 2020-06-22 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 Her-구동된 약물-내성암의 치료 또는 예방을 위한 화합물, 조성물 및 방법
WO2019079729A1 (en) * 2017-10-20 2019-04-25 Purdue Pharma L.P. PHARMACEUTICAL DOSAGE FORMS
US20200323895A1 (en) 2017-11-27 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Compounds, Compositions, and Methods for Treating And/Or Preventing Periodontal Disease
US11547839B2 (en) 2017-12-04 2023-01-10 Clexio Biosciences Ltd. Long acting gastric residence system
WO2019125184A1 (en) 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
WO2019147753A1 (en) 2018-01-24 2019-08-01 The Rockefeller University Antibacterial compounds, compositions thereof, and methods using same
BR112020024048A2 (pt) 2018-05-25 2021-02-17 Temple University-Of The Commonwealth System Of Higher Education composição, e, métodos para descolonizar um organismo microbiano, para destruir ou interromper ou inibir ou reduzir a formação de biofilme de um organismo microbiano e para tratar uma infecção microbiana em um indivíduo.
WO2019231739A1 (en) 2018-05-29 2019-12-05 Cersci Therapeutics, Inc. Compounds for pain treatment, compositions comprising same, and methods of using same
WO2019246145A1 (en) 2018-06-18 2019-12-26 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
TWI826492B (zh) 2018-07-27 2023-12-21 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
AU2019321654B8 (en) 2018-08-17 2025-08-07 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of acute lung injury
WO2020074944A1 (en) 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
US12458601B2 (en) 2018-10-19 2025-11-04 Temple University-Of The Commonwealth System Of Higher Education Tamper-resistant drug dosage forms and methods of making and use thereof
US20220017490A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
US20220017489A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Solid dispersions for treatment of cancer
US12215094B2 (en) 2018-11-02 2025-02-04 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
BR112021014897A2 (pt) 2019-01-30 2021-09-28 Sanifit Therapeutics, S.A. Composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
US20200246316A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
WO2020159588A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
WO2020227603A1 (en) 2019-05-09 2020-11-12 The Feinstein Institutes For Medical Research Hmgb1 antagonist
JP2022538767A (ja) 2019-06-12 2022-09-06 ザ ウィスター インスティテュート アセチルＣｏＡシンテターゼ２（ＡＣＳＳ２）阻害剤およびそれを使用する方法
US11555010B2 (en) 2019-07-25 2023-01-17 Brown University Diamide antimicrobial agents
EP3818983A1 (de) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol-phosphat-verbindungen zur verwendung in der behandlung, progressionshemmung oder verhinderung von kardiovaskulärer verkalkung
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
IL298853A (en) 2020-06-09 2023-02-01 Inozyme Pharma Inc Soluble enpp1 or enpp3 proteins and uses thereof
CN112034057B (zh) * 2020-08-16 2022-04-01 江苏正大清江制药有限公司 一种测定头孢呋辛酯原料中高分子聚合物的方法
EP4015494A1 (de) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Verfahren zur herstellung von löslichen salzen von inositolphosphaten
EP4036097A1 (de) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6-substituierte derivatverbindungen
IL318658A (en) 2022-07-29 2025-03-01 Sanifit Therapeutics S A IP4-4,6-Substituted Derivative Compounds for Use in the Treatment, Inhibition of Progression, and Prevention of Ectopic Calcification
TW202412815A (zh) 2022-07-29 2024-04-01 西班牙商薩尼菲特治療公司 Ip5經取代化合物
IL319372A (en) 2022-09-06 2025-05-01 Hadasit Med Res Service Combinations involving psychedelic drugs for the treatment of chronic schizophrenia and other neuropsychiatric and neurological disorders
WO2025037248A1 (en) 2023-08-14 2025-02-20 Neurim Pharmaceuticals (1991) Ltd. Gal475 compositions and methods of use thereof
WO2025099725A1 (en) 2023-11-09 2025-05-15 Hadasit Medical Research Services And Development Ltd. Conjugates and uses thereof
WO2025162971A1 (en) 2024-01-31 2025-08-07 Sanifit Therapeutics, S.A. Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2025217094A1 (en) 2024-04-08 2025-10-16 University Of Rochester Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
WO2025217096A1 (en) 2024-04-08 2025-10-16 University Of Rochester Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
WO2025217379A1 (en) 2024-04-10 2025-10-16 University Of Rochester Drug treatment for macular degeneration

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
ZA722664B (en) 1971-05-18 1973-01-31 Smith Kline French Lab Lyered bolus for animal husbandry providing for immediate and sustained release of medicament
CH582002A5 (de) * 1972-06-09 1976-11-30 Purdue Research Foundation
US4088798A (en) * 1975-11-11 1978-05-09 Sandoz, Inc. Methods for the preparation of controlled gastric residence time medicament formulations
US4207890A (en) 1977-01-04 1980-06-17 Mcneilab, Inc. Drug-dispensing device and method
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
JPS58134019A (ja) 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
US4629620A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4867969A (en) 1986-02-07 1989-09-19 Alza Corporation Hydrogel formulation for administering non-steroidal drugs
JPS62195323A (ja) 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4816264A (en) * 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
US4789549A (en) * 1987-03-09 1988-12-06 Warner-Lambert Company Sustained release dosage forms
US4891223A (en) * 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US5190760A (en) * 1989-07-08 1993-03-02 Coopers Animal Health Limited Solid pharmaceutical composition
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
AT397345B (de) * 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
DK0542926T3 (da) * 1990-08-07 1995-05-15 Pfizer Brug af grænsefladepolymeriserede membraner i frigivelsesanordninger
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
US5512299A (en) 1992-03-30 1996-04-30 Alza Corporation Method of treating oral inflammatory disease
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1256393B (it) * 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
US5391378A (en) * 1993-02-22 1995-02-21 Elizabeth-Hata International, Inc. Two-part medicinal tablet and method of manufacture
PT711146E (pt) * 1993-07-22 2001-01-31 Pfizer Dispositivos osmoticos com revestimentos permeaveis ao vapor
US5415688A (en) 1993-09-20 1995-05-16 Ameron, Inc. Water-borne polysiloxane/polysilicate binder
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
IT1265240B1 (it) 1993-11-30 1996-10-31 Ekita Investments Nv Compressa farmaceutica a rilascio controllato, di forma lenticolare
HU213407B (en) 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
US5458888A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
MY113429A (en) 1995-02-28 2002-02-28 Univ Temple Controlled release tablet containing swellable polyethylene oxide
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
JP3220373B2 (ja) * 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
ATE200864T1 (de) * 1996-08-29 2001-05-15 Sanofi Synthelabo Tablette mit gesteuerter freisetzung von alfuzosinhydrochlorid
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
WO1998031341A1 (de) 1997-01-14 1998-07-23 Lts Lohmann Therapie-Systeme Gmbh Expandierbares gastroretentives therapie-system mit kontrollierter wirkstofffreisetzung im gastrointestinaltrakt
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
PT998271E (pt) * 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
ES2234139T3 (es) * 1997-08-11 2005-06-16 Alza Corporation Forma de dosificacion de un agente activo de liberacion prolongada adaptada para la retencion gastrica.
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
CA2220038A1 (en) * 1998-01-05 1999-07-05 Amina Odidi Device for the delivery of high dose pharmaceutical, neutraceutical, agricultural, biological, and chemical substances
CA2320900C (en) * 1998-03-19 2009-10-27 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data

Also Published As

Publication number Publication date
DE60123384D1 (de) 2006-11-09
US8329215B2 (en) 2012-12-11
US20150182541A1 (en) 2015-07-02
US7736667B2 (en) 2010-06-15
IL150568A (en) 2007-12-03
US20100272808A1 (en) 2010-10-28
CA2396782A1 (en) 2001-08-09
US20170172930A1 (en) 2017-06-22
US20130164377A1 (en) 2013-06-27
ES2270982T3 (es) 2007-04-16
MXPA02007254A (es) 2002-12-09
AU3466101A (en) 2001-08-14
US20110236485A1 (en) 2011-09-29
DE60123384T2 (de) 2007-08-02
PT1251832E (pt) 2007-01-31
US9597338B2 (en) 2017-03-21
AU767812B2 (en) 2003-11-27
WO2001056544A3 (en) 2002-05-02
EP1251832B1 (de) 2006-09-27
WO2001056544A2 (en) 2001-08-09
US8945619B2 (en) 2015-02-03
US8043630B2 (en) 2011-10-25
JP2003521507A (ja) 2003-07-15
US20030104062A1 (en) 2003-06-05
EP1251832A2 (de) 2002-10-30
HK1050493A1 (en) 2003-06-27
IL150568A0 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
ATE340563T1 (de) DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
NO20014859D0 (no) Raskt dispergerbare doseringsformer inneholdende fiskegelatin
IL153464A0 (en) A controlled release oral drug dosage form
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
ATE211907T1 (de) Osmotisches arzneimittelfreisetzungssystem
BR0307473A (pt) Forma de dosagem farmacêutica para distribuição por via mucosa
CO4940409A1 (es) Tableta cubierta con pelicula para seguridad mejorada del tracto gastrointestinal superior
TR200002207T1 (tr) Slekoksib bileşikleri.
EP1365749A4 (de) Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
AP2003002763A0 (en) Controlled release formulations for oral administration
HU9301672D0 (en) Method for manufacturing solid dosing forms of medicaments with controlled releasing of active agents
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
DK1292303T3 (da) Stabil farmaceutisk formulering omfattende torsemidmodifikation II
SG145717A1 (en) Composition for releasing a weak base for an extended period of time
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
DZ3103A1 (fr) Nouvelles pyrazolo Ä4,3-EÜdiazépines substituées, compositions pharmaceutiques les contenant, utili sation à titre de médicament et procédés pour leurs préparation.
WO2003037296A3 (en) Methods and dosage forms for improving the bioavailability of therapeutic agents
RU2003133155A (ru) Способ эрадикации инфекции helicobacter pylori в желудке
TR200301552A1 (tr) Rofekoksib' in yeni oral farmakolojik formülasyonları.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties